233 related articles for article (PubMed ID: 16597210)
21. Oncologic complications of human immunodeficiency virus infection: changing epidemiology, treatments, and special considerations in the era of highly active antiretroviral therapy.
Klibanov OM; Clark-Vetri R
Pharmacotherapy; 2007 Jan; 27(1):122-36. PubMed ID: 17192166
[TBL] [Abstract][Full Text] [Related]
22. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
[TBL] [Abstract][Full Text] [Related]
23. Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act.
Burgoyne RW; Tan DH
J Antimicrob Chemother; 2008 Mar; 61(3):469-73. PubMed ID: 18174196
[TBL] [Abstract][Full Text] [Related]
24. What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 2.
Ruane PJ; Daar ES
AIDS Read; 2004 Sep; 14(9):487-98. PubMed ID: 15457602
[TBL] [Abstract][Full Text] [Related]
25. German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004).
Salzberger B; Marcus U; Vielhaber B; Arasteh K; Gölz J; Brockmeyer NH; Rockstroh J
Eur J Med Res; 2004 Nov; 9(11):491-504. PubMed ID: 15649858
[TBL] [Abstract][Full Text] [Related]
26. Role of integrase inhibitors in the treatment of HIV disease.
Palmisano L
Expert Rev Anti Infect Ther; 2007 Feb; 5(1):67-75. PubMed ID: 17266455
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
Martinez-Picado J; Martínez MA
Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
[TBL] [Abstract][Full Text] [Related]
28. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
[TBL] [Abstract][Full Text] [Related]
29. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
[TBL] [Abstract][Full Text] [Related]
30. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs.
Perno CF; Moyle G; Tsoukas C; Ratanasuwan W; Gatell J; Schechter M
J Med Virol; 2008 Apr; 80(4):565-76. PubMed ID: 18297706
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of antiretroviral treatment in a South African program: a cohort study.
Fairall LR; Bachmann MO; Louwagie GM; van Vuuren C; Chikobvu P; Steyn D; Staniland GH; Timmerman V; Msimanga M; Seebregts CJ; Boulle A; Nhiwatiwa R; Bateman ED; Zwarenstein MF; Chapman RD
Arch Intern Med; 2008 Jan; 168(1):86-93. PubMed ID: 18195200
[TBL] [Abstract][Full Text] [Related]
32. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.
Moreno-Torres A; Domingo P; Pujol J; Blanco-Vaca F; Arroyo JA; Sambeat MA
Antivir Ther; 2007; 12(2):195-203. PubMed ID: 17503662
[TBL] [Abstract][Full Text] [Related]
33. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
[TBL] [Abstract][Full Text] [Related]
34. The risks and incidence of K65R and L74V mutations and subsequent virologic responses.
Waters L; Nelson M; Mandalia S; Bower M; Powles T; Gazzard B; Stebbing J
Clin Infect Dis; 2008 Jan; 46(1):96-100. PubMed ID: 18171220
[TBL] [Abstract][Full Text] [Related]
35. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
[TBL] [Abstract][Full Text] [Related]
36. Treatment interruptions in HIV-infected subjects.
Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
[TBL] [Abstract][Full Text] [Related]
37. [Resistance to anti-retroviral therapy in Chilean patients with HIV-1 from 2002 to 2005].
Afani S A; Orellana R L; Duarte J P; Acevedo M W; Morales B O; Wolff R M; Vásquez P; Beltrán C
Rev Med Chil; 2007 Oct; 135(10):1237-44. PubMed ID: 18180829
[TBL] [Abstract][Full Text] [Related]
38. HIV type 1 tropism and inhibitors of viral entry: clinical implications.
Weber J; Piontkivska H; Quiñones-Mateu ME
AIDS Rev; 2006; 8(2):60-77. PubMed ID: 16848274
[TBL] [Abstract][Full Text] [Related]
39. Care of the HIV-positive patient in the emergency department in the era of highly active antiretroviral therapy.
Venkat A; Piontkowsky DM; Cooney RR; Srivastava AK; Suares GA; Heidelberger CP
Ann Emerg Med; 2008 Sep; 52(3):274-85. PubMed ID: 18358567
[TBL] [Abstract][Full Text] [Related]
40. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
Hung CC; Hung MN; Hsueh PR; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Huang YT; Lo YC; Hsiao CF; Chang SC
Clin Infect Dis; 2007 Sep; 45(5):e60-7. PubMed ID: 17682981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
